REG - Kanabo Group PLC - Notice of AGM

KanaboAnnouncement

08/06/2022 13:00

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20220608:nRSH1801Oa&default-theme=true

RNS Number : 1801O  Kanabo Group PLC  08 June 2022

 

Kanabo Group Plc.

("Kanabo" or the "Company")

 

Notice of AGM

 

Kanabo Group Plc. (LON: KNB), a medical cannabis R&D Company that focuses
on the distribution of cannabis-derived products for medical patients, and
non-THC products for CBD consumers, announces that its Annual General Meeting
("AGM") will be held at Asserson Law Offices of Central Court, 25 Southampton
Buildings, Holborn, London, WC2A 1AL on Thursday 30 June 2022 at 11:00 am.

 

A notice of AGM, together with a form of proxy and a copy of the annual report
has been sent to the shareholders of the Company (" Shareholders ").  The
notice of AGM will also shortly be available for inspection on the Kanabo
website (https://www.kanabogroup.com/) .

 

For further information, please visit http://www.kanabogroup.com/ or
https://www.voxmarkets.co.uk/listings/LON/KNB
(https://www.voxmarkets.co.uk/listings/LON/KNB) or contact the following:

 

 Kanabo Group Plc                            Via Vox Markets
 Avihu Tamir, CEO
 Peterhouse Capital Ltd (Financial Adviser)  Tel: +44 (0)20 7469 0930
 Eran Zucker / Lauren Riley
 Vox Markets (Investor Relations)            KanaboGroup@voxmarkets.co.uk
 Kat Perez                                   kperez@voxmarkets.co.uk

 

 

About Kanabo Group Plc

Kanabo Group Plc is creating a new standard in the medical cannabis industry
to improve the well-being of millions of people around the world by providing
a better alternative to the smoking of medicinal cannabis flowers. Kanabo,
which was the first medicinal cannabis company to IPO on London Stock
Exchange, has a focus on the distribution of cannabis-derived products for
medical patients and non-THC products for CBD consumers.

 

It has conducted extensive Research & Development to produce high-quality
cannabis extract formulas, innovative medical-grade vaporizers, and various
non-smoking consumption solutions. Kanabo sells a range of medical cannabis
products and wellness CBD products in the Primary Markets, including its
VapePod, which delivers a metered dose with every inhalation.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  NOAEAFKPEDKAEFA